{"id":61207,"date":"2026-03-25T12:55:07","date_gmt":"2026-03-25T04:55:07","guid":{"rendered":"https:\/\/flcube.com\/?p=61207"},"modified":"2026-03-25T12:55:08","modified_gmt":"2026-03-25T04:55:08","slug":"iaso-bio-wins-japan-pmda-approval-for-fucaso-car-t-bcma-therapy-enters-phase-iii-in-relapsed-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61207","title":{"rendered":"IASO Bio Wins Japan PMDA Approval for Fucaso CAR\u2011T \u2013 BCMA Therapy Enters Phase III in Relapsed\/Refractory Multiple Myeloma"},"content":{"rendered":"\n

IASO Biotherapeutics<\/strong> announced receiving tacit clinical approval<\/strong> from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)<\/strong> for Fucaso (equecabtagene autoleucel)<\/strong>, its BCMA\u2011targeted CAR\u2011T cell therapy<\/strong>, enabling initiation of a Phase III international multicenter trial<\/strong> in relapsed\/refractory multiple myeloma (r\/r MM)<\/strong> patients who have received 1\u20112 prior lines of therapy and are lenalidomide\u2011resistant<\/strong> \u2013 advancing the China\u2011origin cell therapy toward Japan commercialization via efficient registration pathway<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>PMDA (Pharmaceuticals and Medical Devices Agency, Japan)<\/td><\/tr>
Product<\/strong><\/td>Fucaso (equecabtagene autoleucel) \u2013 BCMA\u2011targeted CAR\u2011T<\/td><\/tr>
Company<\/strong><\/td>IASO Biotherapeutics (China\u2011based)<\/td><\/tr>
Indication<\/strong><\/td>Relapsed\/refractory multiple myeloma (r\/r MM)<\/td><\/tr>
Patient Population<\/strong><\/td>1\u20112 prior lines of therapy; lenalidomide\u2011resistant<\/strong><\/td><\/tr>
Approval Type<\/strong><\/td>Tacit clinical trial approval (CT103AC004)<\/td><\/tr>
Study Design<\/strong><\/td>International multicenter, randomized, open\u2011label Phase III<\/td><\/tr>
Comparator<\/strong><\/td>Standard of care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Development Status<\/h2>\n\n\n\n
Milestone<\/th>Date\/Status<\/th>Strategic Significance<\/th><\/tr><\/thead>
China Phase III Initiation<\/strong><\/td>June 2024<\/td>First\u2011in\u2011world BCMA CAR\u2011T in lenalidomide\u2011resistant early\u2011line setting<\/td><\/tr>
Trial Progress<\/strong><\/td>“Progressing smoothly”<\/td>Foundation for global expansion<\/td><\/tr>
Japan PMDA Approval<\/strong><\/td>March 2026<\/td>First major ex\u2011China regulatory approval<\/strong>; Asia\u2011Pacific market entry<\/td><\/tr>
Japan Registration Strategy<\/strong><\/td>“Small\u2011sample clinical trial + global overall data support”<\/td>Cost\u2011efficient pathway<\/strong> leveraging China data; accelerated timeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Japan Registration Strategy \u2013 Efficient Pathway<\/h2>\n\n\n\n
Strategy Element<\/th>Implementation<\/th>Commercial Benefit<\/th><\/tr><\/thead>
Small\u2011Sample Japan Trial<\/strong><\/td>Reduced local enrollment requirement<\/td>Significantly reduced independent R&D costs<\/strong> in Japan<\/td><\/tr>
Global Data Integration<\/strong><\/td>Leverage China Phase III data + international multicenter results<\/td>Accelerated review timeline<\/strong>; reduced duplication<\/td><\/tr>
Registration Efficiency<\/strong><\/td>PMDA tacit approval enables immediate trial initiation<\/td>Earlier Japan market entry<\/strong> vs. traditional full\u2011scale Japan\u2011only development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Dimension<\/th>r\/r MM CAR\u2011T Landscape<\/th>Fucaso Position<\/th><\/tr><\/thead>
Approved BCMA CAR\u2011Ts<\/strong><\/td>Abecma (BMS\/bluebird), Carvykti (J&J\/Legend) \u2013 3L+ setting<\/td>Earlier\u2011line positioning<\/strong> (1\u20112L) \u2013 larger addressable population<\/td><\/tr>
Lenalidomide Resistance<\/strong><\/td>~60\u201170% of r\/r MM patients; major unmet need<\/td>Targeted biomarker\u2011defined population<\/strong> \u2013 differentiation from all\u2011comer CAR\u2011Ts<\/td><\/tr>
Japan Market Dynamics<\/strong><\/td>~8,000\u201110,000 MM patients annually; high unmet need; premium pricing<\/td>First China\u2011origin CAR\u2011T<\/strong> in Japan; potential for reimbursement advantage<\/strong> via cost\u2011efficient development<\/td><\/tr>
Global Expansion<\/strong><\/td>China \u2192 Japan \u2192 EU\/US pathway<\/td>Validates China\u2011first development model<\/strong> for cell therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n